Insights

Strategic partnerships Arrivo Bio is actively engaging in co-development through ventures like Arrivo BioVentures LLC and has recent press indicating collaboration with Lamassu Bio on phase 2 human clinical trials, signaling potential for alliance-driven opportunities in joint development, data sharing, and milestone-driven partnerships.

Clinical data visibility Upcoming presentation of RABI-767 clinical data at the EPC 2026 Annual Meeting suggests increasing credibility and interest from investors and industry peers, creating openings for sponsorships, speaker engagements, or data-driven partnerships to accelerate clinical milestones.

Funding and scale With funding around $94M and a revenue range of $10M-$25M, Arrivo Bio shows a solid early-stage financial foundation and growth trajectory, presenting opportunities for strategic investments, licensing deals, or contract research collaborations to expand capabilities and market reach.

Technology and platform A tech stack featuring cloud, web, and content management tools (AWS, Cloudflare, WordPress, Microsoft 365) indicates strong digital infrastructure; explore partnerships in data management, secure collaboration, and digital trial platforms to enhance R&D operations and sponsor-facing dashboards.

Market positioning Positioned as a trusted partner with a focus on drug candidate selection and clinical development, Arrivo Bio presents a compelling target for large biopharma and mid-sized biotech companies seeking experienced CRO-like collaboration for efficient development, potential licensing, or co-development deals.

Similar companies to Arrivo Bio

Arrivo Bio Tech Stack

Arrivo Bio uses 8 technology products and services including Amazon Web Services, Open Graph, RSS, and more. Explore Arrivo Bio's tech stack below.

Arrivo Bio's Email Address Formats

Arrivo Bio uses at least 1 email format:
Arrivo Bio Email FormatsExamplePercentage
FLast@arrivobio.comJDoe@arrivobio.com
100%

Frequently Asked Questions

What is Arrivo Bio's official website and social media links?

Minus sign iconPlus sign icon
Arrivo Bio's official website is arrivobio.com and has social profiles on LinkedIn.

How much revenue does Arrivo Bio generate?

Minus sign iconPlus sign icon
As of October 2026, Arrivo Bio's annual revenue is estimated to be $10M - $25M.

What is Arrivo Bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
Arrivo Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Arrivo Bio have currently?

Minus sign iconPlus sign icon
As of October 2026, Arrivo Bio has approximately 15 employees across 1 continents, including North America. Key team members include Owner: R. D. and Vice President, Scientific Affairs: G. R. Explore Arrivo Bio's employee directory with LeadIQ.

What industry does Arrivo Bio belong to?

Minus sign iconPlus sign icon
Arrivo Bio operates in the Biotechnology Research industry.

What technology does Arrivo Bio use?

Minus sign iconPlus sign icon
Arrivo Bio's tech stack includes Amazon Web Services, Open Graph, RSS, WordPress, Microsoft 365, jQuery Migrate, WP Engine and Cloudflare Bot Management.

What is Arrivo Bio's email format?

Minus sign iconPlus sign icon
Arrivo Bio's email format typically follows the pattern of FLast@arrivobio.com. Find more Arrivo Bio email formats with LeadIQ.

How much funding has Arrivo Bio raised to date?

Minus sign iconPlus sign icon
As of October 2026, Arrivo Bio has raised $94M in funding. The last funding round occurred on Nov 29, 2023.

When was Arrivo Bio founded?

Minus sign iconPlus sign icon
Arrivo Bio was founded in 2015.
Arrivo Bio logo

Arrivo Bio

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Arrivo Bio is a biotechnology research company focused on improving drug development by guiding decision-making from the initial selection of candidate compounds through the entire clinical development process. Based in Morrisville, North Carolina, the firm positions itself as a partner to industry participants and investors by aiming for reliable outcomes and successful product progress through its methodological approach. The company serves clients involved in drug discovery and development, addressing the challenges of translating early research into clinically viable therapeutics. Its stated emphasis is on establishing standards that influence both candidate selection and downstream development, underscoring a specialized role within the broader biotechnology landscape.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $94M

    Arrivo Bio has raised a total of $94M of funding over 2 rounds. Their latest funding round was raised on Nov 29, 2023 as a Series B.

  • $10M - $25M

    Arrivo Bio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.